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Background: We sought to determine whether suboptimal chemotherapy compromised the prognosis of
osteosarcoma patients.
Methods: A total of 132 eligible patients who underwent chemotherapy between 1998 and 2008 were identified in
our database. Information regarding patient demographics, clinical characteristics, and survival status were extracted
for analysis. Optimal chemotherapy was defined as receipt of ≥80% of the planned dose intensity of prescribed
agents within the planned durations.
Results: The use of optimal chemotherapy resulted in an overall survival benefit with P = 0.006. Patients who failed
to complete the optimal chemotherapy protocol had a dismal prognosis of 30.8% overall survival over five years,
whereas those who completed the optimal chemotherapy had an overall survival rate over five years of 65.3%.
Based on multivariate analysis, patients who were treated with a suboptimal protocol had a higher risk of relapse,
metastasis and mortality. The hazard ratio (HR) of recurrence or death for the suboptimal chemotherapy group was
as high as 2.512 over that of the optimal chemotherapy group (HR = 2.512, 95% confidence interval = 1.242 to
3.729).
Conclusions: Chemotherapy is a significant independent prognostic variable, and suboptimal chemotherapy was
found to have a detrimental effect on the outcome of patients with osteosarcoma.
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Osteosarcoma is the most common malignant bone
tumor; it predominantly affects adolescents and con-
tinues to be an extremely aggressive disease despite the
use of neoadjuvant chemotherapy protocols and wide-
margin, limb-salvaging surgery [1]. The five-year overall
survival (OS) rate of osteosarcoma patients of all ages
has been reported to range from 53% to 58% in the United
States and Europe [2].
An approximately 70% long-term event-free survival rate
for osteosarcoma patients can currently be achieved by
using the standard three-drug chemotherapy protocol that
includes cisplatin, doxorubicin and high-dose methotrexate
[3]. The addition of ifosfamide to a three-drug regimen has* Correspondence: shenjingnan@126.com
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reproduction in any medium, provided the orbeen extensively used and tested in several clinical trials
[4-7]. In China, chemotherapy for osteosarcoma has lagged
significantly behind other countries. Most chemotherapy
treatments for osteosarcoma were adopted from other
countries [8]. However, the phenomenon that patients
often abandon treatment prematurely or choose to delay
resuming chemotherapy is quite prevalent but is not ser-
iously recognized in musculoskeletal oncology.
The present study aimed to evaluate the effect of in-
complete or suboptimal chemotherapy on survival and
to discuss possible reasons for lack of compliance to
treatment. We found that suboptimal chemotherapy is
an unfavorable prognostic factor in the overall survival
(OS), event free survival (EFS), relapse free survival and
metastasis free survival of osteosarcoma patients. Inade-
quate finances, poor patient-doctor relationship and psy-
chological and behavioral compromise may contribute
to suboptimal chemotherapy.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical characteristics of the
cohort
Number Percent of total (100%)
Total patients 132 100
Age
≤11(F), ≤12(M) 24 18.2
12 to 14 (F), 13 to 15 (M) 34 25.8






Distal femur 66 50.0
Proximal tibia 35 26.5
Proximal humerus 6 4.5
Proximal fibula 11 8.3












Optimal chemotherapy 52 39.4







F, female; M, Male.
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Patient eligibility
We retrospectively reviewed the medical charts of 410
osteosarcoma patients who were treated at our hospital
between 1998 and 2008. The last follow-up for event-
free survivors was in October, 2010. The minimum
follow-up time was 24 months. The criteria for inclusion
in the study were as follows: (1) Enneking stage IIB [9];
(2) no history of treatment except needle biopsy; (3)
scheduled for neo- and adjuvant chemotherapy; (4) sur-
gery at our institute; and (5) longer than 24 months of
follow-up for event-free patients. Of the 410 patients,
367 were Enneking stage IIB. Patients were excluded for
the following reasons: prior chemotherapy, surgery or
open biopsy at another hospital (n = 32), no treatment
(n = 23), chemotherapy alone (n = 63), or surgery alone
(n = 9). In addition, patients who were followed for less
than 24 months (n = 108) were excluded. Therefore, the
final study population consisted of 132 patients; the clin-
icopathological characteristics of these patients are sum-
marized in Table 1. Several variables were recorded, and
the influence of the variables on survival, local recur-
rence, and metastasis were statistically evaluated. This
study was approved by the Ethical Committee of First
Affiliated Hospital, Sun Yat-Sen University.
Protocol description
Optimal chemotherapy was defined as follows: (1) the ad-
ministration of methotrexate (MTX), cisplatin (DDP),
adriamycin (ADM), ifosfamide (IFO) or their combina-
tions; (2) the administration of MTX at a dose of 8 to 12
g/m2 (with leucovorin‘rescue’ commencing six hours after
the initiation of the MTX infusion), cisplatin at a dose of
100 mg/m2 for four hours followed by 60 mg/m2 of adria-
mycin for 48 hours, and IFO at a dose of 2 to 3 g/m2 for
five days with an injection of mesna (400 mg) after 12
hours of IFO administration; (3) one cycle of chemothe-
rapy (MTX, DDP + ADM, IFO) that took place over 42
days; and (4) patients who received ≥80% of the planned
dose intensity [10]. At least two courses of MTX were
required for induction chemotherapy, and at least three
cycles of triplets (MTX, DDP + ADM, IFO) were applied
after definitive surgical therapy (Figure 1A). At our insti-
tute, IFO was introduced into our optimal protocol in
1999. Prior to that, postoperative chemotherapeutic regi-
mens were the same as the preoperative regimens; after
the inclusion of IFO, poor responders were administered
IFO-containing regimens more frequently, while good
responders were treated with the same regimen as for the
preoperative therapy. The chemotherapy response was
primarily determined based on physical evaluation and
radiographic reassessment according to Response Evalua-
tion Criteria in Solid Tumors (RECIST) criteria. A lesion
in the same plane was consistently measured [11].Study definition
In the survival analysis, the primary end points were
time until death, time until relapse, and time until me-
tastasis. Overall survival (OS) was measured in days
from the date of diagnosis to the date of death.
Metastasis-free intervals were measured from the date of
diagnosis to the date of metastasis (the metastatic loca-
tion was either lung or bone) or death. The relapse-free
interval was measured from the date of diagnosis to the
Figure 1 A Optimal chemotherapy protocol. MTX: methotrexate, DDP: cisplatin, ADM: adriamycin, IFO: ifosfamide. B Age and gender
distribution in this cohort. C Proportion of patients receiving suboptimal chemotherapy and optimal chemotherapy. D Initial MRI of a patient with
osteosarcoma of the right distal femur. T2-weighted MRI shows altered signal intensity involving the distal metaphysis, growth plate and medial
condylar of the right femur with minimal necrosis. E Follow-up after two courses of MTX (8.5 g/m2) and one course of ADM (60 mg/m2) plus
DDP (100 mg/m2) demonstrated a positive response to chemotherapy based on the extent of liquefactive necrosis and cystic changes of the soft
tissue component despite the absence of a significant reduction in size. MRI magnetic resonance imaging.
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measured from the date of diagnosis to the date of any
significant event (metastasis, relapse or death). Patients
who did not develop metastasis or relapse or remained
alive at the final follow-up were censored at that time.
Surgery
Surgical interventions for osteosarcoma included limb
salvage surgery and amputation. Definitive surgical the-
rapy required a wide or radical surgical margin. The
options for postoperative reconstruction included modu-
lar prosthesis, extendible prosthesis, and autograft or
allograft transplantation with plate or intramedullary
interlocking nail. Amputation included simple amputa-
tion, rotationplasty amputation, and modified rotation-
plasty amputation. The surgical type was determined by
the patient’s life expectancy, maturity of epiphysis, pre-
sence of pathological fracture, clinical and surgical clas-
sification, and the patient’s willingness and financial
capacities.
Follow-up
After completing chemotherapy, patients were followed
up for two years with quarterly radiographs of the ope-
rated limb. Computed tomography (CT) of the chestwas performed every three months for two years. There-
after, the same protocol was repeated every six months
for up to five years and then annually for up to the tenth
year after surgery. All of the patients were followed up
for at least two years after diagnosis unless they were
deceased.
Statistics
Both OS and EFS were determined based on the Kaplan-
Meier Survival Analysis, and the results in the different
groups were compared using the log-rank test. Only
variables that were significantly different in the univariate
study were entered into the multivariate analysis using the
Cox proportional-hazards regression model. The analysis
was performed using SPSS 13.0 and P-values of <0.05
were considered to be statistically significant.
Results
Demographic information
Among the total 410 patients, 132 met the inclusion cri-
teria and their charts were reviewed for inclusion in the
study group. The study population included 93 males
and 39 females, with a median age of 16 years (range, 5
to 56 years); 34 (25.8%) patients had undergone the
onset of their growth spurt (12 to 14 (females), 13 to 15
Table 2 Overall survival and event-free survival






Total patients 43.5 ± 5.6 N/A 40.3 ± 5.9 N/A
Age
≤11(F), ≤12(M) 39.8 ± 14.2 34.8 ± 18.2
12 to 14 (F), 13 to (M) 47.6 ± 10.3 43.9 ± 11.2
15 to 39 (F), 16 to 39 (M) 42.2 ± 7.5 39.1 ± 7.8
≥40 50.0 ± 35.4 0.396 37.5 ± 28.6 0.925
Gender
Male 42.8 ± 6.4 37.8 ± 7.0
Female 47.0 ± 10.8 0.104 46.2 ± 11.0 0.063
Location
Distal femur 45.1 ± 8.1 38.6 ± 8.3
Proximal tibia 45.9 ± 9.9 52.9 ± 10.7
Proximal humerus 31.2 ± 45.7 66.7 ± 19.2
Proximal fibula 25.0 ± 20.4 30.7 ± 17.1
Proximal femur 50.0 ± 25.0 0
hip/pelvic 0 0
Other 57.1 ± 18.7 0.752 71.4 ± 17.1 0.696
Pathological fracture
Yes 0 0
No 46.7 ± 5.6 0.193 42.3 ± 5.9 0.759
Subtype
Osteoblast 41.8 ± 5.9 39.2 ± 6.4
Chondroblastic 35.2 ± 17.2 41.7 ± 19.9
Fibroblastic 67.3 ± 27.0 66.7 ± 19.2
Other 0 0.916 37.5 ± 28.6 0.723
Chemotherapy
Optimal chemotherapy 65.3 ± 7.3 55.0 ± 9.0
Suboptimal
chemotherapy
30.8 ± 6.9 0.006* 31.1 ± 7.4 0.005*
Local recurrence
Yes 23.2 ± 12.0 —
No 49.3 ± 6.1 0.135 — —
Distal metastasis
Yes 18.2 ± 8.8 0.001* —
No 61.5 ± 6.5 — —
*, P<0.05; F, female; M, male.
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location affected by osteosarcoma (50%), and the major-
ity of the pathological sub-classifications were the osteo-
blast subtype (Table 1). Fifty-three (39.4%) cases
underwent optimal chemotherapy while 80 (60.6%) cases
did not complete the prescribed chemotherapy protocol.
Among these, 2 cases underwent only preoperative
chemotherapy, 23 cases underwent fewer than 9 cycles
and more than 6 cycles of postoperative chemotherapy
with or without preoperative chemotherapy, and 55
cases underwent fewer than 6 cycles of postoperative
chemotherapy with or without preoperative chemothe-
rapy (Figure 1C). Sixty-three (47.7%) events were
recorded. Local recurrence occurred in 25 cases, includ-
ing 3 cases of isolated local recurrence and 22 cases that
eventually developed metastasis. Metastasis occurred in
57 cases, and the involved sites were the lung (55 cases),
bone (1 case) and other sites (1 case).
Suboptimal chemotherapy was correlated with adverse
overall survival, event free survival, relapse free survival
and metastasis free survival in univariate analysis
The five-year OS and EFS statistics are summarized in
Table 2. The OS for the entire cohort was 43.5 ± 5.6%.
However, patients who adhered to the optimal protocol
had a five-year survival rate of 65.3 ± 7.3%, which was
significantly better than the 30.8 ± 6.9% survival rate for
the suboptimal chemotherapy group (P = 0.013). Similar
results were obtained in EFS: 55.0 ± 9.0% patients were
alive without disease in the optimal chemotherapy
group, but only 31.1 ± 7.4% patients survived longer
than five years without significant findings in the sub-
optimal chemotherapy group. Among the patients with
metastases in the optimal chemotherapy group, 49.0 ±
7.2% survived for five years, while 30.4 ± 6.0% of those
in the suboptimal chemotherapy group was still alive
after five years of follow up. The outcome of patients
with local recurrence in the optimal chemotherapy
group was better than that of patients in the suboptimal
chemotherapy group (five-year survival of 39.5 ± 6.7%
versus 24.7 ± 6.1%) (Table 3).
Suboptimal chemotherapy is an independent unfavorable
factor for overall survival, event free survival and
metastasis free survival
Based on the multivariate analysis, chemotherapy was
found to be an independent risk factor for OS, EFS and
metastasis free survival. The risk of mortality and metas-
tasis was approximately 1.8-fold higher in patients with
suboptimal chemotherapy (hazard ratio (HR) = 1.804,
95% confidence interval (CI) = 1.016 to 3.204). Patients
in the optimal chemotherapy group were more likely to
experience recurrence (HR = 1.670, 95% CI = 0.987 to
2.825), although chemotherapy did not independentlyaffect relapse free survival (P = 0.06) (Table 4). The
Kaplan-Meier survival curves for the aforementioned
data are shown in Figure 2.Discussion
The addition of neoadjuvant and adjuvant chemotherapy
to radical surgery has been demonstrated to improve




Five-year P Five-year P
Total patients 34.4 ± 4.0 N/A 33.6 ± 3.9 N/A
Age
≤11(F), ≤12(M) 39.8 ± 14.2 26.6 ± 14.4
12–14 (F), 13–15 (M) 37.3 ± 10.0 35.4 ± 9.6
15–39 (F), 16–39 (M) 33.3 ± 7.0 33.2 ± 6.7
≥40 37.5 ± 28.6 0.941 37.5 ± 28.6 0.952
Gender
Male 32.1 ± 6.3 31.9 ± 5.9
Female 41.9 ± 10.0 0.090 38.0 ± 9.7 0.053
Location
Distal Femur 37.3 ± 7.7 32.4 ± 7.2
Proximal Tibia 45.9 ± 9.9 41.8 ± 9.4
Proximal humerus 25.0 ± 20.4 25.0 ± 20.4
Proximal fibula 30.7 ± 17.1 46.0 ± 17.5
Proximal Femur 25.0 ± 21.7 0
Hip/Pelvic 0 0
Others 0 0.454 57.1 ± 18.7 0.257
Pathological Fracture
Yes 0 0
No 37.1 ± 5.5 0.319 35.5 ± 5.2 0.386
Subtype
Osteoblast 33.5 ± 5.7 31.9 ± 5.4
Chondroblastic 29.3 ± 15.3 29.3 ± 15.3
Fibroblastic 66.7 ± 19.2 83.3 ± 15.2
Others 45.0 ± 32.2 0.257 33.8 ± 26.0 0.326
Chemotherapy
Optimal Chemotherapy 49.0 ± 7.2 39.5 ± 6.7
Suboptimal
Chemotherapy
30.4 ± 6.0 0.009* 24.7 ± 6.1 0.005*
Local Recurrence
Yes — 13.7 ± 8.0
No — — 40.3 ± 5.8 0.033*
Distal Metastasis
Yes 21.1 ± 6.1 —
No 50.1 ± 7.8 0.001* — —
*, P<0.05; F, female; M, male.
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Long-term survival in localized osteosarcoma has
increased substantially from 10% to 20% (when surgery
was performed as the only treatment) to 50% to 60% [12].
Five-year OS from 17 musculoskeletal oncology institutes
in China ranges from 37.5% to 77.6% [13]. In the present
study, the five-year OS for all patients was 43.5%, which issignificantly lower than the international survival rate for
these patients [14-16]. However, the five-year OS among
patients who completed the optimal chemotherapy regi-
men was as high as 65.3% which is comparable to the
international survival rate. There is a suggestion that many
patients failed to complete the optimal chemotherapy
protocol, and this phenomenon is also observed at other
Chinese hospitals.
A combination drug protocol consisting of four drugs
(DDP, ADM, MTX, and IFO) has been associated with an
overall five-year survival rate of 44% to 65% [17,18]. Inter-
national chemotherapy standards using these four drugs in-
clude the T12/T19 treatment developed by Rosen [19], the
IOR-OS/N-2 treatment developed by Bacci and recommen-
dations by the European Society for Medical Oncology
(ESMO) in 2009 [20,21]. Although efforts have been made
to identify optimized standard chemotherapy protocols that
are suitable for the Chinese population, we do not yet have
a nationwide sarcoma registry system that would support
clinical trials with a large sample size to test standard proto-
cols [8]. Our chemotherapy regimen was based on the four
drugs described above and was a modified version of IOR-
OS/N-2. The differences are as follows: (1) only two
courses of MTX were required for induction chemotherapy
and (2) IFO was routinely used after definitive surgery. For
those who responded poorly to induction chemotherapy,
we administered a more frequent IFO-containing regimen
and/or added second-line drugs. The IOR-OS/N-2 protocol
requires at least two cycles (four to six courses) for induc-
tion chemotherapy, but only two courses of preoperative
medication are required in our protocol. We agree with
Jeon and Bacci that the delayed removal of tumor increases
the risk of systemic metastasis [22,23]. Furthermore, a
smaller need exists for long-term neo-adjuvant therapy to
bridge the gap between biopsy and resection due to the im-
provement of endoprostheses manufacturing. Third, the
concern of non-compliance with long term induction
chemotherapy must be considered. In our experience, two
courses of MTX or two courses of MTX plus one course of
ADM and DDP were adequate to achieve a good response
to induction chemotherapy (Figure 1D and E). With this
modified protocol, patients in the optimal chemotherapy
group achieved an OS rate of 65.3% ± 7.3%, which is com-
parable to that in Bacci’s study [19].
In the univariate study, factors that were significantly
different according to our stratifications are chemothe-
rapy, local recurrence and lung metastasis.
Bajpai et al. showed that there was no significant dif-
ference in survival between the noncompliant versus
compliant group in osteosarcoma [24] but in our study,
patients who failed to complete the optimal chemothe-
rapy protocol had less opportunity to achieve a stable
disease status or complete remission. The reason why
these two studies have different conclusions is obvious.
Table 4 Cox proportional hazards model for the risk of death, relapse or metastasis, relapse alone and metastasis
alone
Overall survival Event free survival Relapse free survival Metastasis free survival
HR 95% CI P HR 95% CI P HR 95% CI P value HR 95% CI P value
Chemotherapy
Suboptimal chemo 1.804 1.016 to 3.204 2.512 1.242 to 3.729 1.670 0.987 to 2.825 1.863 1.159 to 2.996
Optimal chemo 1 0.04 0.006* 1 0.06 1 0.01
Local recurrence
Yes — — — — — — — — — 0.633 0.388 to 1.034
No — — — 0.07
Lung metastasis
Yes 0.511 0.303-0.861 0.01* — — — 0.509 0.312-0.829 0.007* — — —
No 1 — 1 —
*, P<0.05; CI,confidence interval; HR, hazard ratio.
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minimum follow-up time is 24 months. However, chemo-
therapy did not independently affect relapse-free survival
(P >0.05). These data indicate that other factors (such as
surgery) act in combination with chemotherapy to main-
tain local control of the disease. Picci has convincingly
demonstrated that the local failure rate in osteosarcoma
correlates with both the quality of the surgical margins
and the extent of tumor response to induction therapy
[25]. Surgical margins should always be seriously consid-
ered to be equally as important as chemotherapy.
Chemotherapy compliance was defined as adherence to
a prescribed treatment regimen [26]. It can be affected by
psychological and behavioral aspects as well as financial
aspects. The former may include physician’s attitude,
doctor-patient relationship, psychological support from
others and religious convictions [27]. The latter was often
unjustifiable and has social and economic roots. In China,
the high price of drugs (including chemotherapy drugs and
their rescue drugs) has long been blamed for medical ser-
vices being unaffordable for less advantaged people and
has triggered increasing complaints from the public [28].
Moreover, very expensive prosthesis (manufactured both
domestically and abroad) causes some patients to discon-
tinue chemotherapy after surgery. The current basic me-
dical insurance system in China has not yet determined
how to disseminate basic medical insurance coverage to
benefit more patients with malignant tumors and how to
reduce the proportion of personal health expenditures [29].
The possible solutions for unjustifiable chemotherapy
non-compliance may include: (1) Increase the budget for
medical services and restrain the price of chemotherapy
drugs; (2) improve the national medical insurance system
and enlarge the insurance coverage for malignant tumors;
(3) encourage sponsorships and donations from society and
set a charity fund for osteosarcoma patients; and (4) en-
courage domestic prosthesis development. The suggestionsfor justifiable non-compliance are as follow: (1) Strengthen
the physician-patient relationship by providing adequate
time for counseling, correct and accurate information in-
terpretation, patient privacy protection and so on; (2)
strengthen the family and social support system by provi-
ding personal and individualized care, chaplain services or
psychological counseling; (3) strengthen patient education
before and after hospitalization; and (4) strengthen the
follow-up system by telephone, e-mail, and family visits to
keep patients accountable for their timely therapy.
This study included some limitations. First, our study
was limited by its retrospective nature; however, the issue
under investigation could not be studied prospectively.
The prospective cohort study is of superior quality to a
retrospective study in observational research; and the evi-
dence level of a prospective study is higher than that of
retrospective research. Nevertheless, it has the disadvantages
of substantial expense, sensitivity to attrition and lengthy
follow-up time. Desiring to improve our patients’ survival
rates, we conducted this study to investigate the effects of
suboptimal chemotherapy on osteosarcoma prognosis.
Second, our study was devised using data available from
osteosarcoma patients at a single institution, and therefore,
the total number of patients was relatively small. Our
results would be more compelling if a larger number of
patients being treated at different institutions had been
included in the study, but our strict standards for inclusion
naturally limited the size of our study. Our results also
require validation in a large number of patients at differ-
ent institutions. Finally, bias led by the inherent hetero-
geneity of the optimal chemotherapy regimen is difficult
to eliminate.
Conclusions
In summary, we investigated a cohort of osteosar-
coma patients with long term follow-up, suboptimal
chemotherapy compromised the outcome and
Figure 2 A Overall survival for all patients, compared to B Overall survival stratified by chemotherapy. C Event-free survival for all patients,
compared to D Event-free survival stratified by chemotherapy. E Relapse-free survival for all patients, compared to F Relapse-free survival stratified
by chemotherapy. G Metastasis-free survival for all patients, compared to H Metastasis-free survival stratified by chemotherapy.
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http://www.wjso.com/content/10/1/191prognosis of the subjects. Standardization of treat-
ment is deemed necessary in the Chinese osteosar-
coma population, and multicenter clinical trials to
identify optimized chemotherapy drugs and protocols
suitable for Chinese patients must be developed.
Moreover, taking measures to improve patients’ com-
pliance to treatment is of equal importance.
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